{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:15Z","timestamp":1740108315760,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T00:00:00Z","timestamp":1482969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00228-016-2185-z","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T08:06:40Z","timestamp":1482998800000},"page":"471-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France"],"prefix":"10.1007","volume":"73","author":[{"given":"Alicia","family":"Molinier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-9224","authenticated-orcid":false,"given":"Aurore","family":"Palmaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bourrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,29]]},"reference":[{"key":"2185_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","volume":"71","author":"MJ Berg","year":"2008","unstructured":"Berg MJ, Gross RA, Tomaszewski KJ et al (2008) Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71:525\u2013530. doi: 10.1212\/01.wnl.0000319958.37502.8e","journal-title":"Neurology"},{"key":"2185_CR2","first-page":"141","volume":"42","author":"R Gauzit","year":"2012","unstructured":"Gauzit R, Lakdhari M (2012) Generic antibiotic drugs: is effectiveness guaranteed? Med Mal Infect 42:141\u2013148","journal-title":"Med Mal Infect"},{"key":"2185_CR3","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. CPMP\/EWP\/QWP\/1401\/98 Rev.1\/Corr**2010 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf . Accessed 5 december 2016."},{"key":"2185_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/ana.22452","volume":"70","author":"GL Krauss","year":"2011","unstructured":"Krauss GL, Caffo B, Chang Y-T et al (2011) Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol 70:221\u2013228. doi: 10.1002\/ana.22452","journal-title":"Ann Neurol"},{"key":"2185_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2165\/10898530-000000000-00000","volume":"70","author":"AS Kesselheim","year":"2010","unstructured":"Kesselheim AS, Stedman MR, Bubrick EJ et al (2010) Seizure outcomes following the use of generic versus brand-name antiepileptic drugs. Drugs 70:605\u2013621. doi: 10.2165\/10898530-000000000-00000","journal-title":"Drugs"},{"key":"2185_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/j.1875-9114.2012.01099.x","volume":"32","author":"R Talati","year":"2012","unstructured":"Talati R, Scholle JM, Phung OP et al (2012) Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Pharmacotherapy 32:314\u2013322. doi: 10.1002\/j.1875-9114.2012.01099.x","journal-title":"Pharmacotherapy"},{"key":"2185_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40261-015-0351-1","volume":"36","author":"MS Vari","year":"2016","unstructured":"Vari MS, Pinto F, Mencaroni E et al (2016) Safety of overnight switch from brand-name to generic levetiracetam. Clin Drug Investig 36:87\u201391. doi: 10.1007\/s40261-015-0351-1","journal-title":"Clin Drug Investig"},{"key":"2185_CR8","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","volume":"70","author":"J LeLorier","year":"2008","unstructured":"LeLorier J, Duh MS, Paradis PE et al (2008) Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 70:2179\u20132186. doi: 10.1212\/01.wnl.0000313154.55518.25","journal-title":"Neurology"},{"key":"2185_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","volume":"48","author":"F Andermann","year":"2007","unstructured":"Andermann F, Duh MS, Gosselin A, Paradis PE (2007) Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48:464\u2013469. doi: 10.1111\/j.1528-1167.2007.01007.x","journal-title":"Epilepsia"},{"key":"2185_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/pds.1912","volume":"19","author":"K Martin-Latry","year":"2010","unstructured":"Martin-Latry K, B\u00e9gaud B (2010) Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 19:256\u2013265. doi: 10.1002\/pds.1912","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2185_CR11","unstructured":"Pr\u00e9valences des ALD, 2012. http:\/\/www.ameli.fr\/fileadmin\/user_upload\/documents\/Prevalences_2012_mise_en_garde.pdf . Accessed 28 Sep 2016"},{"key":"2185_CR12","unstructured":"Imbaud D, Morin A, Picard S, Toujas F (2012) Evaluation de la politique fran\u00e7aise des m\u00e9dicaments g\u00e9n\u00e9riques. http:\/\/leciss.org\/sites\/default\/files\/Rapport%20IGAS_medicaments%20generiques_2012.pdf . Accessed 26 September 2016."},{"key":"2185_CR13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/pds.3362","volume":"22","author":"C Olesen","year":"2013","unstructured":"Olesen C, Harbig P, Barat I, Damsgaard EM (2013) Generic substitution does not seem to affect adherence negatively in elderly polypharmacy patients. Pharmacoepidemiol Drug Saf 22:1093\u20131098","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2185_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00228-010-0819-0","volume":"66","author":"P Latry","year":"2010","unstructured":"Latry P, Molimard M, B\u00e9gaud B, Martin-Latry K (2010) How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. Eur J Clin Pharmacol 66:743\u2013748. doi: 10.1007\/s00228-010-0819-0","journal-title":"Eur J Clin Pharmacol"},{"key":"2185_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/pds.1717","volume":"18","author":"P Noize","year":"2009","unstructured":"Noize P, Bazin F, Dufouil C et al (2009) Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf 18:310\u2013319. doi: 10.1002\/pds.1717","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2185_CR16","doi-asserted-by":"publisher","first-page":"e0119688","DOI":"10.1371\/journal.pone.0119688","volume":"10","author":"J Rathe","year":"2015","unstructured":"Rathe J, Andersen M, Jarb\u00f8l DE et al (2015) Generic switching and non-persistence among medicine users: a combined population-based questionnaire and register study. PLoS One 10:e0119688. doi: 10.1371\/journal.pone.0119688","journal-title":"PLoS One"},{"key":"2185_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00228-014-1763-1","volume":"70","author":"G Durrieu","year":"2014","unstructured":"Durrieu G, Batz A, Rousseau V et al (2014) Use of administrative hospital database to identify adverse drug reactions in a pediatric university hospital. Eur J Clin Pharmacol 70:1519\u20131526. doi: 10.1007\/s00228-014-1763-1","journal-title":"Eur J Clin Pharmacol"},{"key":"2185_CR18","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00228-013-1539-z","volume":"69","author":"J Rathe","year":"2013","unstructured":"Rathe J, Larsen P, Andersen M et al (2013) Associations between generic substitution and patients\u2019 attitudes, beliefs and experiences. Eur J Clin Pharmacol 69:1827\u20131836. doi: 10.1007\/s00228-013-1539-z","journal-title":"Eur J Clin Pharmacol"},{"key":"2185_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.respe.2013.08.001","volume":"61","author":"A Sommet","year":"2013","unstructured":"Sommet A, Georgel B, Poutrain J-C et al (2013) Diff\u00e9rences de taux de substitution des m\u00e9dicaments g\u00e9n\u00e9riques en Midi-Pyr\u00e9n\u00e9es en fonction des classes pharmaco-th\u00e9rapeutiques. Revue d\u2019\u00c9pid\u00e9miologie et de. Sant\u00e9 Publique 61:539\u2013544. doi: 10.1016\/j.respe.2013.08.001","journal-title":"Sant\u00e9 Publique"},{"key":"2185_CR20","doi-asserted-by":"publisher","first-page":"h1724","DOI":"10.1136\/bmj.h1724","volume":"350","author":"J Wise","year":"2015","unstructured":"Wise J (2015) Doctors are warned not to prescribe generic pregabalin for pain control. BMJ 350:h1724\u2013h1724. doi: 10.1136\/bmj.h1724","journal-title":"BMJ"},{"key":"2185_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/erp.12.83","volume":"13","author":"P Dylst","year":"2013","unstructured":"Dylst P, Vulto A, Simoens S (2013) Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res 13:59\u201372. doi: 10.1586\/erp.12.83","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2185_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/2013.jamainternmed.997","volume":"173","author":"AS Kesselheim","year":"2013","unstructured":"Kesselheim AS (2013) Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med 173:202. doi: 10.1001\/2013.jamainternmed.997","journal-title":"JAMA Intern Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2185-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2185-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2185-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:59:53Z","timestamp":1498359593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2185-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,29]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["2185"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2185-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2016,12,29]]}}}